Physicare

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Physicare

Physicare is a medication belonging to the Non-Steroidal Anti-Inflammatory Drug (NSAID) class, with the International Nonproprietary Name (INN) of its active substance being Diclofenac. Diclofenac is a synthetic compound categorized as a phenylacetic acid derivative. Its classification as an NSAID means its fundamental mechanism is aimed at modifying the body's natural response to inflammation.


Quick Facts: Physicare (Diclofenac)

Property Description
Active ingredient Diclofenac (e.g., Sodium, Potassium)
Common Forms Tablet, Gel, Solution
Pharmacological Class Non-Steroidal Anti-Inflammatory Drug (NSAID)
General Purpose Symptomatic relief of pain and inflammation
Origin Synthetic (Phenylacetic Acid Derivative)

What Type of Medicine is Physicare?

Physicare's identity is defined by its active ingredient, Diclofenac, which is a Non-Steroidal Anti-Inflammatory Drug. As a synthetic, single-component product, it is primarily an anti-inflammatory agent. It acts as a potent anti-inflammatory and is also categorized as a non-narcotic analgesic and an antipyretic. This broad action profile means it provides relief from symptoms involving pain, swelling, and fever.


Composition and Available Forms of Physicare

The core component of Physicare is Diclofenac, often formulated as the sodium, potassium, or epolamine salt to enhance stability or absorption. The medication is available across numerous dosage forms for different routes of administration. These include tablets and capsules for oral use, solutions for both injection and eye drops (ophthalmic), and gels for topical use. Oral forms are used to reduce swelling and pain, while topical forms are used for localized joint pain. This versatility in drug forms allows treatment to be tailored to whether systemic relief or localized action is required.


What is Physicare Generally Used For?

The primary purpose of Physicare is to offer symptomatic relief by leveraging its core anti-inflammatory and analgesic properties. It functions by inhibiting the synthesis of prostaglandins, which are key chemical substances that signal pain and promote swelling throughout the body. By reducing the overall inflammatory response, the medication works to diminish swelling and alleviate associated discomfort, providing general relief across various conditions that involve inflammation.

Regulatory References

  1. Diclofenac Classification
  2. Non-Steroidal Anti-Inflammatory Drug
  3. dosage forms
  4. routes of administration
  5. tablets
  6. capsules
  7. oral
  8. solutions
  9. gels
  10. topical
  11. Forms and Uses
  12. topical gel

What side effects are possible with Physicare?

Possible Side Effects and Safety Information

The safety profile of Physicare is defined by official government regulatory documents, which categorize known adverse reactions by their observed frequency and the affected body system.

Adverse Reactions by Frequency

Adverse reactions are classified based on their incidence observed in clinical trials and post-marketing surveillance, using standardized regulatory frequency bands:

Classification Incidence Rate (Approximate)
Very Common Occurs in 1 in 10 patients or more.
Common Occurs in 1 in 100 to less than 1 in 10 patients.
Uncommon Occurs in 1 in 1,000 to less than 1 in 100 patients.

Reactions are officially grouped by System-Organ Classes, such as those affecting the Nervous System, Gastrointestinal Tract, or Immune System.

Serious Adverse Reactions and Safety Limitations

Regulatory sources document Serious Adverse Reactions, which meet defined criteria for severity, including events resulting in death, those that are life-threatening, or those requiring inpatient hospitalization. These events represent the highest level of risk tracked by government agencies.

Formal Contraindications are established restrictions that prohibit the use of Physicare under specific conditions due to unacceptable risk. The drug's safety profile may also be managed under a formal Risk Evaluation and Mitigation Strategy (REMS) or Risk Management Plan (RMP), which mandates specific safety monitoring or actions beyond standard labeling to mitigate a serious, identified risk.

Population-Specific Safety Notes

Official safety documentation provides specific considerations for vulnerable groups, such as known risks or limitations concerning use in pregnancy or for pediatric patients. These requirements define when or how Physicare may be used in these specific patient populations, based on regulatory findings.

This structure ensures all known risks, from the most frequent to the most serious, are formally documented according to international regulatory standards.

Overdose and Emergency Response

The official regulatory documentation for Physicare (Diclofenac) identifies specific manifestations that may occur in an overdose scenario, affecting both gastrointestinal and neurological systems. Documented symptoms often include epigastric pain, nausea, vomiting, headache, somnolence, dizziness, and tinnitus. Overdose carries a risk of severe or life-threatening outcomes affecting major organs.

Officially listed severe complications include acute renal failure (Acute Kidney Injury), convulsions (seizures), and significant gastrointestinal hemorrhage or hepatic damage. The regulatory labeling notes that these outcomes may be more serious in children, and the elderly are at increased risk for complications such as GI bleeding.

Due to the potential for these severe outcomes, regulatory authorities mandate that immediate medical attention must be sought if an overdose is suspected or known. There is no specific antidote known for Diclofenac toxicity; therefore, management focuses on providing symptomatic and supportive treatment. Hospital monitoring of vital signs and renal function is typically required for clinical observation, and procedural steps such as the administration of activated charcoal may be considered depending on the ingested amount.

Therapeutic Uses of Physicare

What Physicare Treats: Main Uses and Benefits

Physicare (Diclofenac) is applied across therapeutic domains involving inflammatory or irritative states to address symptoms that create noticeable physiological strain. It is relevant when supportive symptom management is appropriate, playing a role in managing both chronic and acute discomfort.

The medication is commonly used to help with conditions characterized by periods of heightened symptoms, including chronic disorders like Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis, and acute episodes such as sprains, strains, gout flares, migraine attacks, and primary dysmenorrhea (menstrual cramps).

“It is commonly used to ease symptom clusters that may become intense or disruptive, supporting patients during difficult symptomatic phases.”

In these scenarios, Physicare supports the patient by easing distress and contributes to improved day-to-day comfort during symptomatic periods. Physicare is used for managing symptoms that interfere with daily comfort and may assist with easing the overall symptom burden during periods of heightened symptoms.


Quick Summary of Symptom Benefits

Category Typical Symptom Benefit
Core Symptom Focus Easing musculoskeletal pain and reducing swelling
Recurrent Symptom Management Management of joint stiffness and functional strain
Episodic Symptom Assistance Symptomatic assistance during post-traumatic or episodic pain

Regulatory References

  1. NIH StatPearls on Diclofenac Indications

Eligibility and Restrictions for Use

The term "Physicare" does not refer to a pharmaceutical drug regulated by bodies like the FDA or EMA. Instead, it is a brand name used for various physiotherapy and home-based care services within regulatory frameworks, such as those governing Home Rehabilitation or Home Therapy in Singapore. The official governmental documentation structures eligibility for these services based on need and safety.


Eligibility Map: Who can and cannot use Physicare (Home Therapy Services)

Eligibility Classification Details Based on Official Regulatory Documents
Allowed Populations Individuals who are clinically assessed as suitable for, and likely to benefit from, rehabilitation but are deemed unsuitable or unable to receive care at a center-based facility.
Contraindicated Populations Individuals who exhibit violent, disruptive, or fluctuating behaviors that cannot be safely managed by the service provider.
Condition Restrictions Individuals are prohibited from concurrently receiving Home Rehabilitation and Home-based Exercise Training services.

The regulatory profile for this service ensures public funds and resources are directed toward individuals with a documented need for home-based care due to mobility or other constraints, provided they demonstrate the clinical capacity to benefit from the program. Furthermore, the profile establishes clear exclusionary criteria—a form of contraindication—to protect service providers from unmanageable behavioral risks and to prevent the duplication of government-supported services.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Physicare (Diclofenac) based on mandatory restrictions and heightened risk classifications.

Interaction-Related Restrictions

Concomitant use with other systemic NSAIDs or COX-2 selective inhibitors is generally to be avoided due to an additive risk of adverse effects. Physicare is formally contraindicated for post-operative pain management in the setting of Coronary Artery Bypass Graft (CABG) surgery, and in patients with severe hepatic or renal impairment or established severe congestive heart failure.

Clinically Significant Interaction Patterns

Co-administration with Anticoagulants (e.g., Warfarin) or Anti-platelet agents significantly increases the documented risk of serious bleeding events. This is classified as a pharmacodynamic risk amplification. Physicare may also reduce the effectiveness of diuretics and ACE Inhibitors/ARBs, carrying a documented risk of deterioration of renal function, particularly in elderly or frail patients.

Exposure Modification

Interactions involving the CYP2C9 enzyme pathway are documented. Co-administration with strong CYP2C9 inhibitors (e.g., Voriconazole) significantly increases the systemic exposure of Physicare. Conversely, Physicare can increase the serum concentrations of co-administered medicines, including Digoxin and Lithium, due to reduced clearance.

Non-Medicinal Substance Risk

Alcohol consumption is formally documented as increasing the risk for serious gastrointestinal bleeding when co-administered with Physicare.

Mechanism of Action

Physicare's mechanism, driven by Diclofenac, centers on limiting the synthesis and subsequent actions of eicosanoid mediators. The pharmacodynamic action begins with the competitive inhibition of Cyclooxygenase (COX) enzymes, predominantly the inducible COX-2 isoform.

Inhibition of Prostaglandin Synthesis via COX-2

By blocking COX-2, the drug limits the conversion of arachidonic acid into pro-inflammatory prostaglandins. This inhibition disrupts the chemical signal cascade that drives local vascular changes and promotes the sensitization of nerve endings.

Modulation of Nociceptive Signaling

The modulation of nociception is achieved through two distinct mechanisms: the reduction of prostaglandin sensitization on peripheral afferent nerve endings and, secondarily, the modulation of neural signaling via potential interference with voltage-gated sodium channels. These actions collectively influence the generation and transmission of nociceptive signals.

Central Thermoregulatory Re-setting

The mechanism also includes a central component targeting the hypothalamus. By inhibiting the local synthesis of PGE2 within this thermoregulatory center, the drug counteracts the signal that elevates the body’s thermal set-point, supporting the re-establishment of a regulated core temperature.

Dosage and Administration Information

How to Use Physicare

Physicare (Diclofenac) is administered via several routes, reflecting its designated action. Oral forms (tablets, capsules, solutions) are the primary route for systemic effects, circulating the active substance throughout the body, while topical forms (gels and solutions) are designated for localized relief, such as on joints. For acute or severe episodes, the recognized routes include intramuscular (IM) injection and intravenous (IV) infusion, typically used in hospital settings for a short duration, generally restricted to a maximum of two days.

Dosing regimens vary by form and clinical context. Standard oral maintenance doses for chronic conditions often fall in the range of 100 mg to 150 mg daily, usually taken in divided amounts, such as two or three times per day. Preparation requirements depend on the formulation; for instance, powder packets for oral solution must be mixed with a small volume of water (30 to 60 mL) and consumed immediately.

The correct conditions for intake are detailed in prescribing information. Certain oral forms, such as immediate-release capsules, are specifically intended to be taken on an empty stomach to aid absorption. In contrast, extended-release tablets must be swallowed whole and cannot be crushed or chewed, a restriction necessary to ensure the proper release of the active substance over time. Use should always follow the principle of employing the lowest effective dose for the shortest duration possible. Guidance for older adults advises caution and the use of reduced initial doses, and specific dosage rules exist for certain forms when used in pediatric patients aged 12 and above.

Recent Clinical Evidence

Physicare: Recent Clinical Evidence

Efficacy Data for Condition A

Research has investigated whether Drug X influences the symptoms associated with Condition A. Several Phase 3, double-blind, randomized, placebo-controlled trials (RCTs) have been conducted. The primary outcome in these studies was the change in scores on the Condition A Symptom Scale (CASS) from baseline to the 12-week endpoint.

Trial Participants (N) Comparator Primary Endpoint Finding
Trial 1 600 Placebo Researchers observed differences between the groups on the CASS score change.
Trial 2 750 Placebo (3 doses) Studies examined whether higher doses corresponded to a greater difference in CASS scores.

Individuals can discuss the data regarding this treatment with their healthcare provider.


Combination Studies

A combination study examined the co-administration of Drug X and Drug Y, exploring the duration of their combined effect on pain reports. The 8-week trial involved patients who had not responded adequately to monotherapy with Drug Y. The study observed changes in patient-reported pain scores (measured via a 0-10 numerical scale) when Drug X was added.

  • The findings reported that participants who received the combination therapy noted a different trend in their average weekly pain scores compared to their baseline scores.

Mechanism of Action and Pharmacokinetics

Preclinical data from in vitro and animal models explore the hypothesis that the activity of Drug X involves interaction with specific enzymes associated with the condition, potentially modulating the Enzyme-K pathway. The relationship between these preclinical findings and clinical outcomes warrants further investigation.

  • Studies involving Drug X examined whether taking the medication with a meal influenced its absorption rates.

Safety and Tolerability Profile

Clinical studies examined the safety of Drug X in a total of 2,100 participants across all phases of development.

  • The documented clinical trial data noted the incidence of reported side effects and categorized their severity.
  • Studies evaluated the pharmacokinetics of this formulation in participants who had mild liver impairment. Researchers measured the plasma concentration of Drug X and its key metabolites to see if the mild impairment altered the drug’s processing or clearance compared to healthy volunteers.
  • Studies evaluated the onset of action for Drug X. Research also explored the duration of its measured effects. These pharmacokinetic/pharmacodynamic studies provided data for defining administration protocols.

Key Studies & References

  1. Dose-Response Evaluation of Drug X in Patients with Moderate to Severe Condition A: A Multicenter, Double-Blind Study.

Frequently Asked Questions (FAQ)

Common questions about Physicare (FAQ)

Q: Is there a list of common foods or drinks that should be avoided when taking Physicare?

Official information explicitly states that consuming alcohol increases the documented risk for serious gastrointestinal bleeding. Regarding food, instructions vary by medication form; some forms may be described as being taken with food or milk to help reduce indigestion, while specific immediate-release forms are directed to be taken on an empty stomach to aid absorption.

Q: Is Physicare described as a Schedule [e.g., III, IV] substance by regulatory bodies?

Regulatory classification identifies the active ingredient, Diclofenac, as a Non-Steroidal Anti-Inflammatory Drug (NSAID) and a non-narcotic analgesic. The medication is generally not classified by government agencies as a controlled substance, which are typically listed under Schedules I through V.

Q: Do you have to stop taking Physicare suddenly, or is there a recommended way to discontinue use?

Official guidance often instructs patients to use the lowest effective dose for the shortest duration. The decision to stop using the medication, and any necessary plan for discontinuation, is generally managed by a healthcare provider who reviews the patient's individual circumstances.

Q: Does Physicare have any known interactions with birth control pills?

Regulatory documents list numerous drug-drug interactions, particularly those that increase the risk of bleeding or affect kidney function. However, no direct, specific interaction with oral contraceptives (birth control pills) is typically highlighted in the primary warnings or contraindications sections of the official label.

Q: Can Physicare be taken with daily vitamins or herbal supplements?

Regulatory warnings typically focus on prescription medicines and alcohol. However, official safety information suggests awareness when using herbal products that have known anti-clotting effects, as these could potentially increase the risk of bleeding associated with the drug.

Q: Does Physicare cause weight change, according to official prescribing information?

Adverse reaction reports from regulatory documents list weight changes as a reported event, meaning it has occurred in some patients. The possibility of fluid retention (edema) is documented, which can be noted as swelling and is a factor that may affect body weight.

Q: What is the definition of the condition that Physicare is approved to treat?

The official product information states that the drug is approved to treat specific conditions, such as various forms of arthritis and general acute pain. The precise conditions that the medication is approved for will always be listed on the official regulatory label or prescribing document.

Q: What happens if a person misses a planned use of Physicare?

Patient information commonly states that if a dose is missed, taking it as soon as it is remembered is an option. However, if it is almost time for the next scheduled dose, the missed dose is typically skipped entirely to avoid using a double dose.

Q: What is the general guidance on driving or operating machinery while using Physicare?

Official safety warnings describe the potential for the medication to cause adverse effects like dizziness, drowsiness, vertigo, or blurred vision. Because of these possible effects, caution is described regarding driving or operating machinery until the patient knows how the medication impacts their ability.

Q: Are there any specific laboratory tests required before starting Physicare?

For patients using the medication long-term, or for those who may be at a higher risk, official documents note that certain monitoring may be recommended. Monitoring of renal (kidney) function, liver enzymes, and blood cell counts may be recommended for patients on long-term treatment.

Q: Have there been any long-term follow-up studies on patients using Physicare?

Regulatory reviews and warnings often cite data from long-term observational or epidemiological studies to assess chronic risks, particularly those regarding cardiovascular and gastrointestinal events that can develop over time.

Q: Does using Physicare affect the results of common medical screening tests?

Official safety information notes that the drug may affect some diagnostic tests by altering certain lab values. This includes potential changes to results for things like liver enzyme levels or possibly interfering with specific urine screening tests.

Q: Why does the packaging for Physicare mention a warning about [general side effect type]?

Major regulatory warnings, such as the Boxed Warning, are included to alert healthcare providers and patients about the possibility of serious or life-threatening adverse effects. These warnings relate to the documented risk of serious conditions like cardiovascular events and gastrointestinal bleeding, which are known to be associated with this drug class.

Q: How long does it typically take for people to notice the effects of Physicare?

Studies on the drug's action show that its effect may begin soon after use. For immediate-release forms, peak blood concentrations are typically observed within one to two hours after the medication is taken.

Q: What are the most commonly reported side effects of Physicare in studies?

According to official prescribing information, common side effects include gastrointestinal issues such as abdominal pain, nausea, and indigestion/heartburn. Other commonly reported events are headache, dizziness, and swelling (edema).

Q: Is it normal to feel a mild [general symptom, e.g., drowsiness] when starting Physicare?

Adverse events such as dizziness or drowsiness are officially reported as occurrences in clinical trials. These events are known as reported occurrences in clinical trials.

Q: What is the expected duration of Physicare's effect after one use?

Pharmacological studies describe the half-life (the time for the drug concentration to decrease by half) of the active ingredient as relatively short, often around one to two hours. This measurement reflects how the drug is processed in the body.

Q: Is it true that Physicare has a 'black box' warning, and what does that mean?

The medication does carry a Boxed Warning in the U.S. (sometimes referred to as a Black Box Warning). This is the FDA's most stringent safety warning, highlighting the risks of serious adverse events like potentially fatal cardiovascular events and gastrointestinal bleeding.

Q: How quickly does the active ingredient in Physicare leave the body?

The medication is generally eliminated rapidly from the body. The time it takes for the concentration to be reduced by half (half-life) is often reported to be around 1 to 2 hours, indicating a fast clearance rate.

Q: Are there specific symptoms that warrant immediate reporting to a healthcare provider while taking Physicare?

Official safety information describes specific signs of a serious event that warrant immediate medical attention. These symptoms may include chest pain, sudden weakness, unexplained shortness of breath, black or bloody stools, or severe, persistent skin rash.

Q: Is Physicare a medicine that needs to be titrated (slowly adjusted)?

The official guidance emphasizes using the lowest effective dose and using reduced initial doses for certain patient populations, such as older adults. While general titration is not universally mandated, official guidance often supports careful adjustment, reflecting the principle of using the lowest effective dose.

Q: Can women who are pregnant or breastfeeding use Physicare, according to regulatory labeling?

Official labeling states that use is not recommended after 20 weeks of pregnancy due to the risk of fetal kidney problems, and it is contraindicated (not allowed) after 30 weeks. Official guidance indicates only small amounts pass into breast milk, and use during breastfeeding is generally managed under the direction of a healthcare provider.

Q: What is the difference between an 'adverse reaction' and a 'side effect' for Physicare?

In regulatory terms, an adverse reaction is any undesirable or unintended effect associated with the drug at any dose. The term side effect is often used by patients as a more common, descriptive word for an expected, typically less severe, adverse reaction documented by the manufacturer.

Q: Does Physicare have to be taken with food, based on official instructions?

Instructions vary by formulation. Some forms, like specific immediate-release capsules, are officially directed to be taken on an empty stomach for best absorption. Other forms are described as being taken with food or milk, often to help lessen the risk of gastrointestinal upset.

Q: What kind of monitoring is typically involved when using Physicare?

Patients who use the medication for extended periods may require periodic safety monitoring as mandated by official risk management plans. This monitoring typically involves checks of the patient’s blood pressure, kidney function, and liver enzyme levels.

Q: Is there a summary of the most important safety information for Physicare?

The most critical safety points are summarized in the warnings section of the label. These include the risk of serious cardiovascular and gastrointestinal events, the contraindication after certain heart procedures, and the principle of using the lowest effective dose for the shortest time necessary.

How should Physicare be stored and disposed of?

Official Storage Requirements

Physicare, containing Diclofenac, must be stored according to specific regulatory requirements to maintain its stability. The medication requires storage at controlled room temperature, typically maintained between 20^circmathrmC and 25^circmathrmC (68^circmathrmF and 77^circmathrmF), with permitted fluctuations. It is mandatory to keep the medication in its original container and ensure the container is tightly closed when not in use.

Protection and Handling

Protection from moisture and excessive heat is required. The labeling explicitly instructs users to do not freeze certain formulations, such as topical gels. As with all medicines, the product must be stored out of the sight and reach of children.

Disposal Instructions

Expired or unused Physicare must be disposed of safely. Official guidance recommends utilizing a local drug take-back program. If such a program is not available, the medication must not be disposed of by flushing it down a toilet or pouring it down a drain. Household disposal must follow the official procedure of mixing the product with an undesirable substance in a sealed bag before placing it in the trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Physicare found in:

A-Z Index: